Ferring and Blackstone Collaborate to Establish Joint Venture Focusing on the Development of Gene Therapy for Bladder Cancer

 Ferring and Blackstone Collaborate to Establish Joint Venture Focusing on the Development of Gene Therapy for Bladder Cancer

Ferring and Blackstone Collaborate to Establish Joint Venture Focusing on Developing Gene Therapy for Bladder Cancer

Shots:

  • Ferring launches a new company FerGene focusing the global development and commercialization of Nadofaragene firadenovec in the US for the patients with Bacillus Calmette-Guérin (BCG) unresponsive, non-muscle invasive bladder cancer
  • Blackstone to invest $400M and its expertise to accelerate the future development and commercialization of Nadofaragene firadenovec while Ferring will invest up to $170M and will get MAA for the therapy if approved by the US FDA.
  • Nadofaragene firadenovec is an adenovirally mediated interferon alfa-2b gene therapy being developed in P-III study as a treatment for patients with high-grade, BCG unresponsive, NMIBC and has received FDA’s PR & BT designation. The US FDA has accepted BLA filing for Nadofaragene firadenovec

Click here to­ read full press release/ article | Ref: Blackstone | Image: VC Circle

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post